Innovative Nanotechnology for Cancer Diagnosis

Nano Discovery is dedicated to the development and commercialization of novel and proprietary high value nanoparticle assay-based molecular diagnostics for cancer.  Our initial target market is prostate cancer, a large market characterized by significant unmet need for improved diagnostic classification of indolent or aggressive tumors.  Current testing procedures result in nearly a third of tumors falling into a “gray area” with an unclear prognosis, with many patients receiving aggressive treatment – often comprising both surgery and chemotherapy / radiation therapy – even though their tumors are actually indolent. The overtreatment of indolent prostate cancers negatively impacts the quality of life for many patients, and places a greater cost burden on the healthcare system.  Nano Discovery’s prostate cancer diagnostic will therefore improve patient outcomes and reduce costs to the healthcare system.

 Value proposition

Current prostate cancer diagnostic testing fails to clearly and accurately classify one third of tumors as indolent or aggressive, resulting in a significant number of unnecessary drug treatments and surgical procedures.   Nano Discovery, Inc. is developing a novel, proprietary prostate cancer diagnostic with the potential to:

1. Identify which patients have indolent tumors and can be spared chemotherapy, radiation and surgical treatment

2. Identify which patients have aggressive tumors that carry a high risk of metastasis and death, and should be considered for treatment with chemotherapy, radiation therapy and / or surgery

Product Pipeline

Tumor-immune system interactions are involved in many types of cancer.  Our technology platform is focused on the detection of tumor-immune system interactions. We are developing a pipeline of diagnostic products spanning various cancer types using our platform technology.  Monoclonal antibody drugs have emerged as one of the most promising approaches in cancer therapy.  However, not all patients respond to monoclonal antibody anti-cancer therapies, resulting in suboptimal outcomes for patients and significant unnecessary costs to the healthcare system.  Preliminary studies using our technology suggest that our new nanoparticle test may be used to predict the therapeutic outcome of antibody drugs.